MAXHEALTH and ASTERDM, both in Hospital/Nursing Management. Monthly data through 2026-10-14. Change the comparison →
Share price change since Aug '20, the first month all 2 have a price: MAXHEALTH +703%, ASTERDM +418%.
Rebased at 2020-08. Monthly closes from each company's history.
Months with a missing value are left as gaps.
The share price return over 3 years, split into net profit growth, share count change and the change in P/E.
MAXHEALTH: share price rose 49% over 3 years: +34 pts from net profit growth, +15 pts from the P/E change.
Not shown for ASTERDM: earnings were negative at one end of the window or there is not enough history.
Segments are percentage points of the price return: price = P/E × net profit ÷ share count. These are the same numbers each company's own page shows.
Each cell is the company's percentile rank among its own sector peers that month. Darker is higher-ranked. Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Percentiles use today's listed companies in the sector and need at least 5 peers with a value.
| Metric | MAXHEALTH | ASTERDM |
|---|---|---|
| Share Price | ₹854.60 | ₹675.70 |
| Market Cap | ₹82997 cr | ₹58989 cr |
| P/E | 57.0x | 109.9x |
| P/B | 7.7x | 14.0x |
| P/S | 9.5x | 12.1x |
| ROCE | 15.0% | 12.0% |
| ROE | 13.5% | 12.8% |
| Operating margin | 25.0% | 20.0% |
| Revenue (TTM), indexed to 100 | ₹8712 cr | ₹4876 cr |
| Net Profit (TTM) | ₹1457 cr | ₹363 cr |
| Debt / Equity | 0.3x | 0.6x |
| Cash Conversion Cycle | -110d | -112d |
| Promoter holding | 23.7% | 40.4% |
| FII Holding | 41.8% | 10.5% |
| DII Holding | 29.9% | 27.6% |
| 12M momentum | -25.5% | -0.4% |
| Drawdown from Peak | -33.0% | -17.8% |
| Cash conversion (3Y) | 1.2x | 0.2x |
| Interest cover | 7.8x | 5.2x |
| Share Count Change (1Y) | 0.1% | 3.6% |
| Volatility (1Y) | 26.3% | 29.0% |
Latest month in the data: 2026-10. Highlight marks the higher value, or the lower value for P/E, P/B, P/S, debt, working-capital days, share count change and volatility. It marks a number, not a better investment.
Comparison is descriptive and historical. Highlights mark the higher or lower value on a metric, not a better investment. Not investment advice; ApnaFunda is not a SEBI-registered research analyst.